Houston Center for Cisplatin Resistance in Head and Neck Cancer
The Houston Center for Acquired Resistance Research (H-CARR)
This center works to find why head and neck cancers stop responding to cisplatin, to spot that change early, and to find ways to make treatments work again for people with head and neck cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11182512 on NIH RePORTER |
What this research studies
This center brings scientists and clinicians together to study why head and neck squamous cell carcinomas become resistant to cisplatin. They will map genetic and metabolic changes in tumors, use non-invasive imaging to watch tumor metabolism, and test blood-based markers like circulating tumor cells to detect resistance. Projects combine lab experiments, analysis of patient samples, and advanced imaging to identify targets and strategies to overcome resistance.
Who could benefit from this research
Good fit: People with head and neck squamous cell carcinoma who are receiving or have received cisplatin, especially if their cancer is not responding or has recurred, would be the most relevant participants.
Not a fit: People without head and neck cancer or those never treated with cisplatin are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, the work could produce tests to detect cisplatin resistance earlier and new approaches to restore treatment sensitivity.
How similar studies have performed: Previous laboratory and clinical studies have identified some resistance mechanisms and blood markers, but combining metabolomics, imaging, and circulating tumor cell detection in this integrated way is relatively new and not yet proven to reverse resistance.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Myers, Jeffrey Nicholas — University of Tx Md Anderson Can Ctr
- Study coordinator: Myers, Jeffrey Nicholas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.